MSACL 2025 Abstract

Unrealized Gains: Advancing Toxicology Methods with Multi-Factorial HPLC-MS/MS Optimization in Oral Fluid and Urine Matrices

Phillip R. Gibbs
Clinical Lab Consulting, Lexington, KY

Phillip Gibbs, PhD (Presenter) Clinical Lab Consulting, LLC

Presenter Bio: Dr. Phillip Gibbs serves as Chief Science Officer at Clinical Lab Consulting, LLC, where he provides technical guidance to clinical laboratories specializing in toxicology testing with HPLC-MS/MS. As an NRCC certified Toxicological Chemist with over 30 years of biotechnology experience, Dr. Gibbs focuses on analytical instrumentation and method development for clinical toxicology applications.

Dr. Gibbs earned his Bachelor of Science in Chemical Engineering from MIT (1991) and Doctorate of Philosophy in Biomedical Engineering from the University of Houston (2001). His clinical laboratory experience includes serving as Laboratory Director at multiple laboratories, including Limestone Diagnostics, where he supervised clinical sample analysis and maintained regulatory compliance.

At Clinical Lab Consulting, Dr. Gibbs specializes in supporting toxicology testing operations, advising clients on implementing emerging technologies such as TOF and pharmacogenetics, and improving existing systems through advances in recombinant hydrolytic enzymes and chromatography media. He utilizes multivariate statistical techniques including design of experiments (DOE) for process optimization in clinical laboratory settings.

Relevant Financial Disclosures (within past 24 months, reported on Aug 15, 2025) No relevant financial relationship(s) to disclose. Conflict mitigation NOT REQUIRED.

INTRODUCTION:
Toxicology laboratories routinely employ HPLC-MS/MS methods with manufacturer default settings on a subset of available parameter settings, potentially limiting analytical performance and sensitivity. In addition, many automated optimization programs do not account for two-factor interactions. A truly global parameter optimization accounting for interactions with these less common settings remains a critical yet underexplored aspect of analytical chemistry that significantly affects detection limits, quantitative accuracy, and method reliability. Traditional approaches rely on standard operating conditions and lack systematic evaluation of key instrumental parameters. This study addresses the gap between common chromatographic assumptions, default instrument settings, and optimized analytical performance in toxicology applications for oral fluid and urine matrices across multiple mass spectrometry platforms.

OBJECTIVES:
The primary objective was to evaluate analytical gains achievable through systematic HPLC-MS/MS parameter optimization compared to manufacturer default conditions on Sciex and Shimadzu systems. Specific aims included: (1) assessing effects of mobile phase additives on ionization efficiency and chromatographic performance; (2) optimizing electrospray ionization source parameters including gas flows, temperatures, and voltages; and (3) conducting compound-specific optimization of multiple reaction monitoring (MRM) transitions and collision energies using non-standard protocols versus automated optimization. Secondary objectives were to quantify sensitivity improvements, evaluate method robustness, and develop optimization protocols applicable to various forensic analyte classes and sample matrices.

METHODS:
A systematic multi-factorial approach employed oral fluid and urine matrices with representative panels including stimulants/illicit drugs, opioids/opiates, benzodiazepines, non-benzodiazepine hypnotics, antidepressants, barbiturates, antipsychotics, anticonvulsants, anesthetics/dissociatives, muscle relaxants, and ethanol biomarkers. Mobile phase optimization evaluated common volatile organic acids, associated ammonium salts, and ammonium fluoride using definitive screening design (DSD). Source parameter optimization on Shimadzu platforms used response surface methodology (RSM) to evaluate nebulizing gas flows, heating gas flows, interface temperature, DL temperature, heat block temperature, and drying gas flows. Equivalent parameters were examined on the 4500 Sciex platform for ethanol biomarkers. Interface voltage optimization employed a custom experimental design for the 8060NX and single factor experiments for the 8050, which lacks the ion focus voltage parameter available in the NX source configuration. Compound-specific parameters, including collision energies and MRM transitions, were optimized using manufacturer-automated fragment selection or stepwise manual methodology for both platforms. Performance metrics included integrated area counts, signal-to-noise ratios, limits of detection and quantification (LOD/LOQ), linearity, precision, accuracy, and assessment of ion suppression or enhancement.

RESULTS:
Optimized conditions showed significant improvements over default parameters. Analyte area counts increased by approximately 1.3 to more than 10-fold across target analytes, with source settings and interface/ion focus voltages providing the most significant gains. Mobile phase optimization confirmed acetic acid as the preferred phase modifier when negative mode analysis was included, while ammonium fluoride improved positive mode analysis but suppressed negative mode signals. Source parameter optimization identified nebulizing gas and heating gas flow as most critical, with optimal drying gas flow differing significantly between the 8060NX and 8050 platforms. Interface voltage showed significant improvements compared to default tune file settings on both Shimadzu platforms, and optimal ion focus parameter setting diverged significantly from the default setting for the 8060NX. Compound-specific MRM transition and filter settings resulted in average signal enhancement of 5-30% compared to default values.

DISCUSSION:
The multi-factorial optimization approach yielded substantial analytical improvements over manufacturer defaults, revealing unrealized potential in routine toxicology methods. Sensitivity improvements exceeding 10-fold for some analytes have direct implications for detecting lower analyte concentrations in forensic samples, potentially expanding detection windows A systematic multi-factorial approach using employed oral fluid and urine matrices for investigative purposes. This systematic approach provides a framework for forensic laboratories to enhance existing methods without requiring new instrumentation, underscoring the importance of moving beyond default conditions toward evidence-based method optimization in forensic toxicology.